Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

455.17USD
26 May 2017
Change (% chg)

$-0.53 (-0.12%)
Prev Close
$455.70
Open
$456.70
Day's High
$459.25
Day's Low
$453.46
Volume
157,674
Avg. Vol
299,825
52-wk High
$464.38
52-wk Low
$325.62

Latest Key Developments (Source: Significant Developments)

Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr
Monday, 22 May 2017 05:45pm EDT 

May 22 (Reuters) - Sanofi Sa :Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients.Regeneron pharmaceuticals inc - in u.s., kevzara will be marketed by regeneron and sanofi genzyme, specialty care global business unit of sanofi.Regeneron pharmaceuticals, inc says in clinical trial program, sarilumab was statistically significant.Regeneron - final decision on marketing authorization application for kevzara in european union will be made by european commission in coming months.Regeneron pharmaceuticals inc - u.s. Wholesale acquisition cost of kevzara is $39,000/year for 200 mg and 150 mg doses.  Full Article

Regeneron and Sillajen report immuno-oncology clinical study agreement
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Sillajen Inc <215600.KQ>::Regeneron and Sillajen announce immuno-oncology clinical study agreement for combination treatment in kidney cancer.Regeneron - phase 1b clinical trial will evaluate combination of regeneron's pd-1 inhibitor regn2810 and Sillajen's pexa-vec, an oncolytic virus.Regeneron Pharmaceuticals - under terms of agreement, trial will be solely conducted, funded by sillajen based upon mutually developed study design.Regeneron Pharmaceuticals Inc - co, Sanofi is developing regn2810 both alone and in combination with other therapies for treatment of various cancers.Regeneron Pharmaceuticals- open-label trial for phase 1b dose-escalation study is expected to begin later this year.Regeneron Pharmaceuticals- phase 1b dose-escalation study will initially open in Korea, with expansion to sites in U.S..  Full Article

Regeneron says over 3,500 new prescriptions been written for Dupixent
Thursday, 4 May 2017 09:41am EDT 

May 4 (Reuters) - Regeneron Pharmaceuticals Inc -:Regeneron Pharmaceuticals says over 3,500 new prescriptions have been written for Dupixent, which translates into over 900 prescriptions : Conf Call.Regeneron CEO says on the U.S. Patent litigation, we and Sanofi, have been granted oral argument date of June 6 at the court of appeals regarding Praluent.Regeneron CEO says could get a decision on the Praluent appeal before the end of the year : Conf Call.Regeneron says expects the potential approval in Europe for Kevzara in the second quarter of 2017 : Conf Call.Regeneron says Eylea maintained its market position in the anti-VEGF market in the first quarter : Conf Call.Regeneron says based on coversations with payers, we think we should recieve broad coverage for Dupixent by the end of the year : Conf Call.Regeneron says sales of Praluent were impacted from the injunction ruling : Conf Call.Regeneron says we continue to be disappointed by the uptake of PCSK9 class, but remain optimistic about heart data expected early next year : Conf Call.Regeneron says U.S. Eylea net sales in Q1 were impacted by slight decrease in distributor or inventory as well as increase in gross to net margin.Regeneron says Eylea gross to net percentage changed after co started offering a discount regardless of volume for competitive reasons : Conf Call.Regeneron says Eylea gross to net percentage also changed due to small increase in the number of medicaid patients : Conf Call.  Full Article

Regeneron Pharmaceuticals says it received subpoena
Thursday, 4 May 2017 08:23am EDT 

May 4 (Reuters) - Regeneron Pharmaceuticals Inc : :Regeneron Pharmaceuticals Says in JanuarY 2017, company received subpoena from U.S. Attorney's office for the district of Massachusetts .Regeneron Pharmaceuticals says subpoena requesting documents relating to support of 501(c)(3) organizations that provide financial assistance to patients.Regeneron Pharmaceuticals says subpoena requesting documents concerning its provision of financial assistance to patients.Regeneron pharmaceuticals says company is cooperating with investigation.  Full Article

Regeneron Q1 non-gaap earnings per share $2.92
Thursday, 4 May 2017 06:30am EDT 

May 4 (Reuters) - Regeneron Pharmaceuticals Inc ::Regeneron Pharmaceuticals Inc - q1 eylea u.s. Net sales $854 million versus $781 million.Regeneron Pharmaceuticals Inc- total revenues, which include product revenues , increased by 10 pct to $1.319 billion in q1 of 2017.Regeneron reports first quarter 2017 financial and operating results.Qtrly non-gaap earnings per share $2.92.Qtrly gaap earnings per share $2.16.Regeneron pharmaceuticals inc - sees 2017 eylea u.s. Net product sales single digit percentage growth over 2016.Sees 2017 capital expenditures $300 million - $350 million.Q1 earnings per share view $3.06, revenue view $1.30 billion -- Thomson Reuters I/B/E/S.Fy2017 revenue view $5.48 billion -- Thomson Reuters I/B/E/S.Regeneron pharmaceuticals inc - in q1 of 2017, global net sales of praluent were $36 million, compared to $13 million in q1 of 2016.  Full Article

Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA
Friday, 28 Apr 2017 01:00am EDT 

April 28 (Reuters) - Sanofi :Regeneron and Sanofi announce Kevzara® (sarilumab) Biologics License Application resubmission accepted for review by U.S. FDA.Per Prescription Drug User Fee Act (PDUFA), new target action date is May 22, 2017.European Commission expected to make a final decision on marketing authorization application for Kevzara in EU in coming months.  Full Article

Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Sanofi :Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Monthly dosing schedule now approved in both United States and European Union.  Full Article

Regeneron says FDA approved for praluent injection
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc -:Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.  Full Article

Regeneron Pharmaceuticals say CEO Leonard Schleifer's 2016 total compensation was $28.3 mln - SEC filing
Tuesday, 25 Apr 2017 07:41am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc :Regeneron Pharmaceuticals Inc - CEO Leonard Schleifer's 2016 total compensation was $28.3 million versus $47.5 million - SEC filing.Regeneron Pharmaceuticals Inc - CFO Robert Landry's 2016 total compensation was $5.2 million versus $8.2 million - SEC filing.Regeneron Pharmaceuticals Inc - President George Yancopoulos's total compensation in 2016 was $27.77 million versus $40.30 million.  Full Article

Regeneron announces Evinacumab has received FDA breakthrough therapy designation
Thursday, 6 Apr 2017 07:00am EDT 

Regeneron Pharmaceuticals Inc : Regeneron announces Evinacumab has received FDA breakthrough therapy designation for homozygous familial hypercholesterolemia (HOFH) .Regeneron Pharmaceuticals - Regeneron reported positive interim phase 2 results for Evinacumab in Hofh patients, is currently planning a phase 3 trial.  Full Article

More From Around the Web

UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.